Skip to main content
. 2021 Apr 17;12(1):1273–1285. doi: 10.1080/21655979.2021.1911211

Figure 5.

Figure 5.

Biomarker validation. (a) Differential expression between tumor and matched non-carcinoma samples. (b) Expression in LUAD samples with different tumor stages. (c) Association between expression and overall survival time. (a) CAV1. (b) CFD. (c) CLEC3B. (d) FMO2